Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

  1. Waalewijn, H.
  2. Chan, M.K.
  3. Bollen, P.D.J.
  4. Mujuru, H.A.
  5. Makumbi, S.
  6. Kekitiinwa, A.R.
  7. Kaudha, E.
  8. Sarfati, T.
  9. Musoro, G.
  10. Nanduudu, A.
  11. Lugemwa, A.
  12. Amuge, P.
  13. Moore, C.L.
  14. Rojo, P.
  15. Giaquinto, C.
  16. Colbers, A.
  17. Gibb, D.M.
  18. Ford, D.
  19. Turkova, A.
  20. Burger, D.M.
Aldizkaria:
The Lancet HIV

ISSN: 2352-3018

Argitalpen urtea: 2022

Alea: 9

Zenbakia: 5

Orrialdeak: e341-e352

Mota: Artikulua

DOI: 10.1016/S2352-3018(21)00292-7 GOOGLE SCHOLAR lock_openSarbide irekia editor

Objetivos de desarrollo sostenible

Datuen iturria: Scopus